ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00263159
Recruitment Status : Completed
First Posted : December 7, 2005
Last Update Posted : December 28, 2007
Sponsor:
Information provided by:
University Ghent

Brief Summary:
The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

Condition or disease Intervention/treatment Phase
Asthma Procedure: Pharmaceutical care for asthma patients Not Applicable

Detailed Description:
The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients. Patients will be randomly allocated to the control group (= no input from pharmacist) or intervention group (= with pharmaceutical care at baseline and follow-up visits over 6 months).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 221 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Pharmaceutical Care for Asthma Control Improvement
Study Start Date : January 2006
Actual Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources




Primary Outcome Measures :
  1. The difference between study groups in the change of asthma control from baseline and follow-up visits [ Time Frame: after 1, 3 and 6 months ]

Secondary Outcome Measures :
  1. Peak flow [ Time Frame: after 3 and 6 months ]
  2. Knowledge of asthma and treatment [ Time Frame: after 6 months ]
  3. Asthma quality of life questionnaire (AQLQ) [ Time Frame: after 6 months ]
  4. Therapy adherence
  5. Inhalation techniques [ Time Frame: after 6 months ]
  6. Smoking [ Time Frame: after 6 months ]
  7. Asthma exacerbations [ Time Frame: after 6 months ]
  8. General Practitioner (GP) visits, emergency room visits and hospitalisations
  9. Working days lost and school days lost


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with persistent asthma
  • Asthma treatment for at least 12 months
  • Regular visitors of the participating community pharmacy

Exclusion Criteria:

  • Severe co-morbidity
  • > 10 pack-years smoking history
  • Asthma Control Test score < 15 or =25

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00263159


Locations
Belgium
University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Ghent
Investigators
Principal Investigator: Guy Brusselle, MD, PhD University Hospital, Ghent

Additional Information:
ClinicalTrials.gov Identifier: NCT00263159     History of Changes
Other Study ID Numbers: 2005/320
First Posted: December 7, 2005    Key Record Dates
Last Update Posted: December 28, 2007
Last Verified: December 2007

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases